| Name | Title | Contact Details |
|---|
Open Biosystems is a Huntsville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Clear skin can be life-changing, but it`s not easy to see a dermatologist. At Curology, we provide prescription medications custom-formulated for each patient`s skin and shipped directly to their door. We tailor the entire Curology experience specifically for patients with acne and anti-aging concerns, allowing us to provide incredibly personalized, effective and affordable care at scale. We`ve assembled a committed team of dermatology providers and created a secure online platform, bringing professional acne care and prescription treatment to tens of thousands of people who wouldn`t otherwise be able to access or afford it. Curology helps people see tremendous, long-term improvements previously accessible only to a small percentage of the population. Our formulas are already on tens of thousands of sinks across the US. Our technology enables 1:1 chats with real dermatology providers and lets users to share their journeys with an engaged and growing community. Members can upload photos and track their progress over SMS, as well as browse and post digital postcards to share victories and encourage others. Curology is headquartered in the beautiful Hayes Valley neighborhood of San Francisco.
VNA Healthcare Partners of Ohio is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
DMS Health Group is a Fargo, ND-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.